Cadrenal Therapeutics(CVKD) - 2023 Q4 - Annual Report

We have two issued U.S. patents directed to tecarfarin, and a pending provisional application. The expiration date of the issued patents is April 8, 2024 for both our composition of matter patent and our method of treatment patent, not including any possible patent term extension. Foreign patents corresponding to the tecarfarin patents expire in 2025. In the absence of (i) future ODD marketing exclusivity granted by the FDA, (ii) future market and data exclusivity granted by regulatory agencies and (iii) ad ...